How to choose a healthcare research partner: a scorecard and build vs buy guide
Most healthcare research partners are judged on price and panel size, which is why studies stall. This scorecard weighs the criteria that actually predict clean clinician data, plus a build vs buy call.
Use the weighted scorecard in this post to choose a healthcare research partner that can reach verified clinicians, physicians, and HCPs in weeks rather than months, and use the build vs buy framework below to decide whether to run it in-house at all. The single criterion that separates a partner worth paying for from a panel that will waste your budget is not price or headcount, it is whether they can prove that every respondent is a real, licensed, practicing clinician in the specialty you need.
A note on fairness and accuracy: This comparison is based on publicly available information and secondary research. Vendors update their pricing, features, and positioning over time, so please confirm the current details with each provider directly before you decide. We aim to be objective and fair. Every company covered here is a strong option in the space, and the best choice depends on your specific needs.
If you already know you need verified clinicians fast, you can skip the evaluation and Book a demo with CleverX. CleverX gives research and insights teams on-demand access to more than 10 million verified B2B and B2C professionals across 150+ countries, including practicing clinicians and HCPs, with results in days rather than the weeks a traditional agency or panel takes.
This is the decision companion to our overview of B2B healthcare market research and reaching verified clinicians, physicians, and HCPs. That piece explains why the vertical is hard and who you need; this one gives you the tool to choose a partner and the framework to decide whether to build or buy.
Why most healthcare partner choices go wrong
Teams usually choose a healthcare research partner on two visible numbers: cost per complete and panel size. Both are the wrong primary signals. A large panel full of unverified respondents is worse than a small verified one, because in healthcare a single professional survey-taker posing as an oncologist does not just add noise, it inverts conclusions. If the person answering your pricing or messaging questions has never prescribed the drug class you are studying, you are not getting cheap data, you are getting confidently wrong data that a real decision will be built on.
The second failure is treating all clinicians as interchangeable. A partner that can field 5,000 nurses quickly may be unable to reach 25 interventional cardiologists at academic medical centers, which is the sample your study actually needs. Reach into a specific specialty at a specific seniority is a different capability from raw volume, and it is the capability that usually binds.
The scorecard below forces both issues into the open by weighting verification, specialty reach, and compliance above price.
The healthcare research partner scorecard
Rate each partner from 1 (poor) to 5 (excellent) on each criterion, multiply by the weight, and total the weighted scores. The weights reflect what predicts clean, decision-grade clinician data. Adjust them to your own context, but resist the urge to inflate the price weight.
| Criterion | Weight | What a 5 looks like | What a 1 looks like |
|---|---|---|---|
| Identity and credential verification | 25% | Verifies name, employer, specialty, and seniority against trusted professional data before the study | Relies only on a self-reported screener |
| Specialty and seniority reach | 20% | Can reach narrow specialties and specific seniority on demand | Only broad categories like “physician” or “nurse” |
| Compliance posture | 20% | Explains HIPAA, GDPR, adverse event handling, and Sunshine Act transparency without prompting | Cannot speak to compliance beyond a generic privacy line |
| Speed to a verified sample | 15% | Verified respondents in days | Weeks of recruitment before fielding starts |
| Data quality controls | 10% | Active fraud, duplicate, and straight-lining checks plus re-verification | No controls beyond completion rate |
| Incentive and fair-market-value handling | 5% | Handles clinician incentives at fair market value with clean documentation | Flat cash with no documentation |
| References in your therapeutic area | 5% | Named references in your category | No relevant references |
To use it, build a short column per vendor, score each line honestly from the vendor’s actual answers rather than their sales deck, and compute weighted score = raw score x weight. A partner that scores 5 on price but 2 on verification will land well below a partner that is average on price and excellent on verification, which is exactly the ranking you want.
How to pressure-test each line
Verification is the line that vendors most often inflate, so ask the mechanism, not the claim. “How do you know this respondent is a practicing rheumatologist?” should produce a concrete answer about matching identity and credentials against professional sources, not “they passed our screener.” The US Centers for Medicare and Medicaid Services publishes Open Payments data that lists physicians and their affiliations, and the US National Plan and Provider Enumeration System issues the NPI registry; a serious partner can describe how it reconciles respondents against authoritative professional data like this rather than trusting a checkbox.
Compliance is the second line vendors gloss over. A credible partner should reference the privacy regimes that apply, such as HIPAA in the US and the GDPR in Europe, and the healthcare market research codes maintained by bodies like the British Healthcare Business Intelligence Association and ESOMAR. They should also explain adverse event handling: if a clinician mentions a safety issue with a product during your study, the partner needs a process to capture and route it, a requirement the FDA MedWatch program exists to support. If a vendor cannot speak to any of this, score the line a 1 regardless of how good the panel sounds.
Build vs buy: when to run healthcare research in-house
Once you can score partners, the prior question is whether to use one at all. The honest answer depends on three variables: frequency, staffing, and continuity.
Build an in-house healthcare panel only if all three are true: you run healthcare studies more or less continuously rather than a few times a year, you have compliance and panel operations people to own verification, consent, and incentive administration, and you can keep clinicians engaged between studies so the panel does not decay. Clinicians are among the hardest audiences to retain, because their time is scarce and clinical demands are relentless, so an in-house panel that is not fed and maintained loses value fast.
Buy access to a verified network if your healthcare research is intermittent, if you do not have dedicated compliance and panel staff, or if your specialties and geographies shift study to study. For most insights, product, and commercial teams this is the realistic case, and the economics favor buying by a wide margin once the hidden costs of building are counted.
The real cost drivers in build vs buy
The build decision is rarely about software. The costs that dominate are recruitment of hard-to-reach specialties, credential verification, consent and re-consent, incentive administration at fair market value, and attrition. The US Physician Payments Sunshine Act, administered through CMS Open Payments, means clinician incentives have to be handled and in some cases reported with care, which is a compliance workload most teams underestimate. The American Medical Association’s guidance on the physician workforce and the shortages documented by bodies like the Association of American Medical Colleges explain why clinician time is only getting scarcer and more expensive to secure, which pushes the build case further toward buy for most teams.
For a general treatment of this decision beyond healthcare, our guide to enterprise B2B market research build vs buy walks through the same logic across verticals. The healthcare-specific twist is that verification and compliance carry more weight, which is why they dominate the scorecard above.
Fit the partner to the study, not the study to the panel
A partner can be excellent and still be wrong for a given study. Match the choice to what the decision needs. If you are testing a message with 15 specialists, depth of specialty reach and verification matter most, and raw panel size is almost irrelevant. If you are sizing demand across a broad clinician population, speed to a verified sample and quantitative reach matter more. Our recruitment guides on how to recruit physicians and clinicians for research and how to find healthcare professionals for UX research cover how to translate a study’s needs into a recruitment spec you can hand to a partner, and our overview of the best platform for healthcare IT and clinical decision-maker research looks specifically at the decision-maker end of the market.
The same decision discipline applies in adjacent regulated verticals. If your work spans finance as well, see our companion on how to run fintech B2B research fast with a 2-week plan template, and if you also research software audiences, use the B2B SaaS buyer research screener and recruitment checklist.
Where CleverX fits
CleverX is built for the capability the scorecard weighs most heavily: proving that every respondent is a real, verified professional. The network holds more than 10 million verified B2B and B2C professionals across 150+ countries, including practicing clinicians and HCPs, and identity and work profiles are verified against trusted professional data before anyone enters a study. That is what lets teams reach a narrow specialty at a specific seniority and get decision-grade answers in days rather than the weeks a traditional agency or panel build takes.
We will not claim to be the right fit for every study. If your research is continuous enough and your compliance staffing deep enough to justify an in-house panel, build it. But if you need verified clinicians for a focused study and you need them soon, that is exactly what the network is for.
Score your current options against the table above, run the build vs buy check, and if buying wins, Book a demo with CleverX to see how fast a verified clinician sample can be in your therapeutic area.
Frequently asked questions
How do I choose a healthcare research partner?
Score partners against weighted criteria instead of price alone. The criteria that predict clean clinician data are verification method, specialty and seniority reach, compliance posture, speed to a verified sample, data quality controls, and incentive handling. Weight verification and compliance most heavily, because a cheap panel that cannot prove a respondent is a practicing cardiologist will cost you far more in bad decisions than it saves. Use the scorecard in this post to rate each vendor from one to five per criterion and multiply by the weight.
What should a healthcare research vendor scorecard include?
A useful scorecard rates six to eight criteria: how the partner verifies that a respondent is a real, licensed, practicing clinician, how deeply it can reach specific specialties and seniority, its compliance posture around HIPAA, adverse event reporting, and transparency rules, its speed to a verified sample, its data quality controls against fraud and professional survey-takers, its incentive and fair-market-value handling, and its references in your therapeutic area. Weight each criterion, score every vendor from one to five, and compare totals.
Should I build a healthcare panel in-house or buy access to one?
Build only if healthcare research is continuous, you have compliance and panel operations staff, and you can keep clinicians engaged between studies. For most teams running a handful of studies a year, buying access to an always-on verified network is faster and cheaper, because the hidden costs of building are recruitment, verification, re-consent, incentive administration, and attrition, not the software. The build vs buy framework in this post lays out the real cost drivers.
How do you verify that a research participant is a real clinician?
Credible verification checks identity and credentials against professional data rather than trusting a self-reported screener. That means confirming a participant’s name, employer, role, specialty, and seniority against trusted professional sources before they enter the study. In healthcare this matters more than in any other vertical, because a professional survey-taker claiming to be an oncologist can quietly corrupt an entire dataset and the decision that rests on it.
How long should healthcare research take with the right partner?
With an always-on verified network, a focused healthcare study runs in two to four weeks: roughly one to two weeks to field interviews or a survey plus analysis. The slow variable is almost never the method, it is sourcing and verifying the right specialty at the right seniority. A partner that can match and verify practicing clinicians on demand compresses the timeline more than any other single factor, which is why speed to a verified sample belongs on the scorecard.
What compliance rules apply to healthcare market research?
Healthcare research touches privacy rules such as HIPAA in the US and GDPR in Europe, adverse event reporting obligations when a respondent mentions a product safety issue, transparency rules such as the US Physician Payments Sunshine Act that governs how clinician incentives are reported, and market research codes of conduct from bodies like BHBIA and ESOMAR. A credible partner should be able to explain how it handles each of these, which is why compliance posture is a weighted line on the scorecard.